Alvotech and JAMP Pharma Receives Health Canada Approval for Jamteki (Biosimilar, Stelara)
Shots:
- Alvotech and JAMP Pharma have received marketing authorization from Health Canada for Jamteki (AVT04), developed by the former company
- Jamteki has been approved in two presentations: a 45mg/0.5mL pre-filled syringe with a passive safety device for subcutaneous injection (PFS-SD) and a 90mg/mL PFS-SD
- Jamteki, mAb and biosimilar to Stelara (ustekinumab), targets IL-12 and IL-23 involved in inflammatory responses. It is approved in Japan and Canada while EMA recommended market authorization in the EU, Norway, Iceland, and Liechtenstein
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech & JAMP Pharma Expands its 2020 Agreement for Two Biosimilar Candidates in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
